Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor

6Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Secondary glioblastoma is a rare brain tumor characterized by a mutation in isocitrate dehydrogenase, which is reported to lead to epigenetic modification. Patients with secondary glioblastoma experience poor survival and quality-of-life outcomes due to the disease's aggressiveness and a lack of targeted therapies. In this report, a patient with a secondary glioblastoma was treated with a histone deacetylase inhibitor, an epigenetic drug with potent anti-inflammatory properties, in addition to the standard regimen. The patient showed very favorable survival and quality-of-life measures, and a restoration of several neuro-metabolites as measured by spectroscopic magnetic resonance imaging.

Author supplied keywords

Cite

CITATION STYLE

APA

Gurbani, S. S., Weinberg, B. D., Salgado, E., Voloschin, A., Velazquez Vega, J. E., Olson, J. J., … Shim, H. (2020). Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor. Oxford Medical Case Reports, 2020(3), 87–90. https://doi.org/10.1093/omcr/omaa006

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free